TScan Therapeutics, Inc. - 8-K Filing
TScan Therapeutics stockholders approved an amendment to increase authorized voting common shares from 300 million to 600 million on May 20, 2026. The vote passed with 35,913,605 votes for and 3,177,381 against. Katina Dorton and R. Keith Woods were elected as Class II directors. (Items: 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On May 20, 2026, TScan Therapeutics, Inc, 5.07 to this Current Report on Form 8-K, at the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Rest, 9.01 Financial Statements and Exhibits 3)
Tickers: $TCRX